Characterisation of anti-CD52 antibodies alemtuzumab and chimeric 2E8 IgG.

<p>Antibodies were characterised by: (a) Direct binding of antibodies to HUT78 cells using flow cytometry; (b) Competition against alemtuzumab (with murine constant regions) for binding to CD52 on the surface of HUT78 cells using flow cytometry; (c) ADCC using REH⁺⁺ target cells (average of 4 PBMC donors for effector cells).